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Session 6 was entitled ‘Who would have thought it!’ and 
comprised four separate presentations that had in 
common that the inferred conclusions of their titles 
would not necessarily have been inferred from perceived 
wisdom.
Professor Smith’s presentation was ‘Designing adjuvant 
treatment based on biological measurements in the 
neoadjuvant setting’. He provides informed and personal 
reﬂ   ection on the strengths and weaknesses of neo-
adjuvant therapy both as a research tool and in routine 
clinical practice. Th   is comes from an expert who is ideally 
placed to make such observations since the research 
group at the Royal Marsden Hospital has made a number 
of signiﬁ  cant contributions to this ﬁ  eld.
When neoadjuvant therapy was ﬁ  rst introduced many 
researchers and clinicians hoped it would provide better 
out  comes than standard adjuvant therapy and/or im  prove 
breast conservation rates. When longer term out  comes 
(for example, disease free survival, overall survival) were 
shown not to be better, attention turned, as Professor 
Smith highlights, to trying to replace adjuvant with 
neoadjuvant studies, which would give outcome data 
many years earlier. In addition, it was thought that 
neoadjuvant treatment would increase understanding of 
biological mechanisms of speciﬁ  c agents and help in the 
development of new therapeutic targets and agents.
Professor Smith gets to the heart of the issue very 
quickly - the weaknesses associated with response rates 
(clinical complete response (cCR) or pathological com-
plete response (pCR)) as endpoints. He systematically 
addresses the problem of pCR with referenced examples: 
it does not always predict outcome; it only applies to a 
minority of tumours; it does not apply to oestrogen 
receptor-positive tumours; it is of no use for endocrine 
therapy; and you only get the result after the treatment is 
ﬁ   nished. He then turns his attention to the use of 
biological markers as predictors of outcome - both short 
term (for example, response) and long term (for example, 
survival) and shows that these two have not yet been 
validated. He also makes the important point that most 
neoadjuvant therapy studies have been performed on 
larger tumours and that the results may not be 
transferable to patients with smaller, better prognosis 
tumours. He does not oﬀ   er any potential solution to 
address this latter problem in the neoadjuvant setting.
He ﬁ  nally focuses on short term, peri-operative ‘window 
of opportunity’ studies, which potentially provide greater 
applicability to the majority of patients. While Professor 
Smith makes a good scientiﬁ  c case for this approach, the 
potential beneﬁ  ts he highlights remain to be conﬁ  rmed 
and validated.
It is now well recognized that in both early and 
advanced disease the aromatase inhibitors (AIs) are more 
eﬃ   cacious than tamoxifen while the side eﬀ  ect proﬁ  le of 
AIs is diﬀ  erent from tamoxifen. With the latter, a number 
of the side eﬀ  ects are not preventable and at the same 
time are potentially life threatening (for example, 
thrombo-embolic disease, endometrial cancer) while 
with the AIs the majority are not directly life threatening 
and are amenable to preventative treatment (musculo-
skeletal adverse events). Th  e clinical problem is that 
musculoskeletal side eﬀ  ects are both very common and 
can be a cause for patients discontinuing AI therapies. 
Professor Ingle addresses the topic ‘Pharmacogenomics 
explain musculoskeletal adverse events of aromatase 
inhibitors’. His manuscript looks at whether there might 
be a pharmacogenomic explanation for these musculo-
skeletal side eﬀ  ects.
It is important to appreciate both the strengths and 
potential weaknesses of the data presented. For example, 
the data are based on samples obtained as part of a large, 
well conducted randomized clinical trial that included 
two types of AI (a non-steroidal and a steroidal agent) in 
a matched case control study. On the other hand, the 
data are based on a single study that is limited mainly to 
Caucasians. Th  e group did not start with an a priori
hypothesis that it sought to prove but rather applied a 
genome-wide association study as a way of identifying a 
gene(s) of interest. Th   is approach identiﬁ  ed only one SNP 
of real interest out of over half a million searched. 
Professor Ingle’s group then looked for any known 
functions associated with this SNP and proposed a link  © 2010 BioMed Central Ltd
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chronic inﬂ  ammation. In the end the researchers come 
up with a working hypothesis for the mechanism of 
musculoskeletal side eﬀ   ects associated with AIs. Th  is 
moves science forward in that we now have a new 
hypothesis. However, this requires both validation in a 
diﬀ  erent dataset and conﬁ  rmation that the SNP truly has 
a causative relationship and not simply one of association.
An issue of debate over the recent years has been the 
potential clinical importance of genetic variation in 
tamoxifen metabolism with respect to outcome. It is well 
known that 4-hydroxytamoxifen and, in particular, 
4-hydroxy N-desmethyltamoxifen, ﬁ  rst identiﬁ  ed by Lien 
and co-workers in 1989 [1], binds to the oestrogen 
receptor with an aﬃ     nity much higher compared to 
tamoxifen itself. Th   is metabolite, later named endoxifen 
by Dr Flockhardt and his team [2], has received much 
attention due to the ﬁ   nding that the key regulatory 
enzyme in endoxifen production, CYP2D6, harbours a 
polymorphism separating individuals into poor 
metabolizers (low endoxifen concentration) versus good 
metabolizers (high endoxifen concentration).
Conﬂ  icting evidence has linked this polymorphism to 
tamoxifen eﬃ     cacy in general and to potential drug 
interactions inﬂ  uencing outcome among tamoxifen users 
in particular. Multiple compounds, antidepressants in 
particular, are metabolized by CYP2D6; yet clinical data 
presented are conﬂ  icting. Th   us, at the American Society 
of Clinical Oncology (ASCO) meeting in 2009 two retro-
spective patient registry studies (one from the US, the 
other from the Netherlands) addressing the potential 
impact of CYP2D6-interacting compounds on outcome 
in patients treated with tamoxifen reached completely 
opposite conclusions [3,4].
In her presentation, Dr Pritchard carefully reviews 
pharmacokinetic and pharmacogenetic data related to 
the issue. Th   ereafter, she presents a comprehensive survey 
of clinical evidence with respect to the inﬂ  uence  of 
CYP2D6 polymorphism status on outcome in patients 
treated with tamoxifen in general and the potential 
importance of interacting compounds. Th  e inﬂ  uence of 
selective serotonin reuptake inhibitors (SSRIs) on 
tamoxi  fen metabolism may vary between diﬀ  erent 
compounds; evidence suggests a potential detrimental 
role of paroxetine but not other SSRIs [5]. However, as Dr 
Pritchard states in her presentation; no consensus has 
been reached regarding incorporating CYP2D6 genotype 
testing in routine clinical practise.
Th   e last subject to be discussed during this session was 
the role of angiogenesis and angiogenesis inhibitors to 
breast cancer, presented by Dr Harris. While there is a 
good theoretical rationale for antiangiogenetic therapy 
[6], so far clinical studies have revealed moderate eﬀ  ects 
in diseases like ovarian cancer (ASCO 2010) and adjuvant 
therapy for colorectal cancer (ASCO 2009). Th   us, at this 
years ASCO meeting a combined analysis of the three 
studies evaluating chemotherapy with and without 
bevacizumab in metastatic breast cancer revealed a 
signiﬁ  cant improvement with respect to progression-free 
but not overall survival [7].
In his presentation, Dr Harris defends clinical results 
achieved with anti-vascular endothelial growth factor 
(VEGF) therapy, comparing the beneﬁ   ts from VEGF 
inhibition to other targeted therapies, including 
ixabepilone as well as AIs. He further provides an elegant 
overview of the VEGF receptor family, including the 
potential biological role of mRNA splice variants and, in 
particular, the potential role of VEGF-2 polymorphisms 
[8]. He concludes his presentation commenting that 
antiangiogenic therapy is remarkably active, considering 
no predictive markers or targets identifying sensitive 
tumours have been identiﬁ  ed. Clearly, the jury is still out, 
and more data, in particular from translational research 
studies, are needed before a ﬁ  nal verdict may be reached 
on antiangiogenic therapy in breast cancer.
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